中新健康讯（记者 王晓峰）4月11日，国家医疗保障局在京召开新闻发布会，针对近期社会关注的“药品集中采购（集采）影响企业创新”言论，医药价格和招标采购司司长丁一磊明确表示，高价药品并不等同于真正的创新，且高价格往往伴随着高昂的销售推广费用。
丁一磊指出，在药价过高的时期，药品价格中通常有30%-40%用于销售和市场推广，这部分费用并不直接贡献于药品的研发创新。他强调，集采制度的目标是通过规模化采购降低药品价格，减轻患者经济负担，而非阻碍医药企业的创新发展。
国家医保局表示，集采可以挤出药品价格中的水分，使得企业更专注于研发，而不是过度依赖销售推广。同时，集采节约下来的医保资金，可以用于支持真正有创新价值的药品，形成良性循环，鼓励企业进行原创性研发。
发布会上，医保局还透露，未来将继续完善集采政策，确保药品质量和供应稳定，同时保障企业的合理利润，以实现医保、企业、患者三方共赢的局面。
此次发布会的回应，旨在澄清公众对集采政策的误解，表明国家在推进医药改革过程中，兼顾了药品可及性、价格合理性和企业创新动力的平衡。
英语如下：
**News Title:** “China’s Medical Insurance Bureau Denies集采Undermines Innovation: High Drug Prices ≠ Genuine Innovation, High Sales Promotion Costs”
**Keywords:** Medical Insurance Bureau press conference,集采and innovation, drug prices, sales expenses
**News Content:**
**Xinhua Health News** (Reporter Wang Xiaofeng) On April 11, the National Medical Insurance Bureau (NMIB) held a press conference in Beijing, addressing recent concerns that the “centralized drug procurement (集采) affects corporate innovation.” Ding Yilei, the director of the Department of Pharmaceutical Prices and Bidding and Procurement, explicitly stated that high drug prices do not necessarily equate to genuine innovation and that such prices often come with substantial sales and marketing expenses.
Ding highlighted that during periods of excessively high drug prices, 30%-40% of the cost usually goes towards sales and marketing, which does not directly contribute to research and development of innovative medicines. He emphasized that the goal of the集采system is to reduce drug prices through bulk purchasing, alleviating patients’ financial burdens, rather than hindering the innovation of pharmaceutical companies.
The NMIB affirmed that the集采mechanism aims to eliminate inefficiencies in drug pricing, allowing companies to focus more on research and development rather than over-reliance on sales promotion. Moreover, the savings from集采can be allocated to support genuinely innovative drugs, fostering a virtuous cycle that encourages original research and development.
During the press conference, the bureau also revealed its intention to further refine the集采policies, ensuring drug quality and supply stability while safeguarding reasonable profits for enterprises, thus creating a win-win-win scenario for the healthcare system, companies, and patients.
This response at the press conference aims to dispel misunderstandings about the集采policy, demonstrating the country’s commitment to balancing drug accessibility, price rationality, and corporate innovation incentives in its healthcare reform efforts.
【来源】http://www.chinanews.com/life/2024/04-11/10196682.shtml
Views: 1